Tag: Regulatory

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Seeley Holdings Ltd. (the “Company”) announces that the Company has entered into an agreement with Pasinex Resources Limited (the “Issuer”) to convert an aggregate principal amount of $1,116,636.85 of debt (the “Settlement Amount”) owing by the Issuer to the Company into common shares of the Issuer (the “Common Shares”) on a non-brokered private placement basis pursuant to the accredited investor exemption in section 2.3 of National Instrument 45-106 - Prospectus and Registration Exemptions (the “Debt Settlement Transaction”). The Company will acquire ownership and control of 14,888,491 Common Shares (the “Settlement Shares”) in exchange for the settlement of the Settlement Amount at a price of $0.075 per Settlement Share.

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Flutter Entertainment (NYSE: FLUT; LSE: FLTR) (“Flutter”) the world’s leading online sports betting and iGaming operator today announces the extension of its long-term strategic partnership with Boyd Gaming Corporation (“Boyd”) to 2038 and the buyout of Boyd’s 5% stake in FanDuel Group (“FanDuel”), together “the Agreement”.

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform^™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”).

SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.